Tebotelimab anti-tumor activity correlates with baseline immune activity in the TME as predicted by IFN-γ-regulated gene expression or LAG-3 expression levels, providing approaches to enrich for responsive patients that can be explored in future clinical studies. This evidence concerns the gene IFNG and neoplasm.